Tyrosine-Based Linkers for Peptide Release Kinetics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutically active peptides or proteins face challenges such as high clearance in vivo, unreliable release kinetics, and the production of toxic side products during polymer degradation, limiting their efficacy and safety.
Innovation Solution
Development of tyrosine-based linkers that form a pH-dependent, non-toxic prodrug system where a carbamate on the phenolic group of tyrosine is cleaved by an internal amine, releasing the peptide or protein without toxic byproducts, allowing for controlled and predictable pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polymer matrices are used to form injectable depot of peptides or proteins, then the release kinetics can be quite unreliable with high inter patient variability, but the approach attempts to reduce clearance in vivo
Solution Approach 1:
The patent introduces a polymer-protein conjugate as an intermediary system where the active substance is covalently bound to a polymer carrier through a specific linker. This intermediary structure provides controlled release kinetics while reducing inter-patient variability, resolving the contradiction between reliable release and adaptability to different patients.
Solution Approach 2:
The patent modifies the release parameters by using a polymer conjugate system with specific molecular weight and composition (e.g., poly(lactic-co-glycolic acid) with controlled lactide:glycolide ratios). These parameter changes enable predictable release kinetics while accounting for inter-patient physiological variations.
2Duration of action of stationary object
If permanent PEGylation is used to enhance solubility and increase half life, then clearance is reduced, but the PEGylation reduces efficacy of drug substance
Solution Approach 1:
The patent employs a dynamic, reversible linker system that allows the polymer-protein conjugate to release the active protein at controlled rates. This dynamic approach maintains extended half-life through polymer attachment while preserving efficacy by enabling the protein to become available in its active form, unlike permanent PEGylation which irreversibly masks the protein.
Solution Approach 2:
The patent segments the modification approach by using a cleavable linker that divides the polymer attachment from the active protein function. This segmentation allows the protein to perform its therapeutic function while the polymer provides pharmacokinetic benefits, resolving the contradiction between extended half-life and maintained efficacy.
3Ease of operation
If enzymatic activation of the linker is used in carrier prodrugs, then the linker can be removed in vivo, but esters are cleaved very readily and unpredictably causing high inter patient variability
Solution Approach 1:
The patent replaces the biochemical enzymatic cleavage mechanism with a pH-dependent chemical hydrolysis mechanism. This substitution provides more predictable and controllable linker cleavage kinetics that are less susceptible to inter-patient variability in enzyme levels and activity, while still enabling in vivo release of the active protein.
4Productivity
If cascading linkers with masking groups are used, then the peptide or protein can be released, but the masking group removal is the rate limiting step requiring enzymatic mechanism
Solution Approach 1:
The patent extracts and eliminates the complex multi-step enzymatic activation mechanism from the linker design. By using a direct pH-dependent hydrolysis mechanism, the system achieves protein release without requiring masking groups or rate-limiting enzymatic steps, simplifying the overall structure while maintaining or improving release efficiency.
5Ease of manufacture
If non covalent binding of drug molecule in polymer matrix is used, then injectable depot can be formed, but production can harm the sensitive drug substance or undergo side reactions during degradation
Solution Approach 1:
The patent introduces a covalent polymer-protein conjugate as an intermediary that protects the sensitive protein drug substance from harmful degradation reactions. The protein is chemically bonded to the polymer through a stable linker, preventing the protein from undergoing harmful side reactions that would occur in non-covalent polymer matrices during production and storage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a stable and controlled release of peptides or proteins at physiological pH, avoiding toxic side products and ensuring consistent pharmacokinetics, thus enhancing the therapeutic efficacy and safety of the drug.
Implementation Method 1
a carbamate on the phenolic group of tyrosine is cleaved by an internal amine, releasing the peptide or protein
Implementation Method 2
an internal amine, that is protonated at acidic pH gets activated at higher (neutral) pH to act as a nucleophile attacking the phenolic carbamate
Data Source
AI summary
The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.